Starling Oncology
STLN
116 hedge funds and large institutions have $119M invested in Starling Oncology in 2026 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 51 increasing their positions, 27 reducing their positions, and 26 closing their positions.
1,368% more call options, than puts
Call options by funds: $9.35M | Put options by funds: $637K
89% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 27
77% more capital inflows, than outflows
Capital inflows: $33.3M | Capital outflows: $18.8M
0.11% more ownership
Funds ownership: 39.12% → 39.23% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
1% less funds holding
Funds holding: 117 → 116 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$2.4M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$1.92M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.87M |
| 4 |
BlackRock
New York
|
+$1.57M |
| 5 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CenterBook Partners
Greenwich,
Connecticut
|
-$4.48M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.12M |
| 3 |
Massar Capital Management
Stamford,
Connecticut
|
-$1.42M |
| 4 |
GatePass Capital
Independence,
Ohio
|
-$1.28M |
| 5 |
FreeGulliver LLC
New Orleans,
Louisiana
|
-$1.27M |
STLN Hedge Fund Activity: Q1 2026 in Review
116 of the 8,231 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q1 2026, worth a combined $119M — down 13% from $137M a quarter earlier.
Fund positioning in STLN was balanced in Q1 2026: 26 funds opened new positions, 26 closed out, 51 added to existing stakes and 27 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $2.4M. The largest seller was CenterBook Partners, cutting an estimated $4.48M.
- 116 institutional investors held Starling Oncology (STLN) as of Q1 2026, down from 117 in Q4 2025.
- Funds reported $119M of Starling Oncology stock for Q1 2026, down 13% quarter-over-quarter.
- 26 funds opened new Starling Oncology positions in Q1 2026 and 26 closed out, a net change of 0 holders.
- The largest Starling Oncology buyer in Q1 2026 was Goldman Sachs, an estimated $2.4M added.
- The largest Starling Oncology seller in Q1 2026 was CenterBook Partners, an estimated $4.48M sold.
Based on aggregated 13F filings for Q1 2026.